INTRODUCTION: Proteasome inhibitors (PI) and histone deacetylase inhibitors (HDACi) have
demonstrated synergistic pre-clinical activity in multiple myeloma (MM). The goals of this …

INTRODUCTION. There is substantial pre-clinical data demonstrating single agent and
synergistic activity of the proteasome inhibitor (PI) bortezomib and deacetylase inhibitors (DACi) …

We have conducted a Phase II trial (TIDEL) in de-novo CML patients using imatinib 600 mg
initially, increasing to 800 mg if specified response criteria were not met, including: major …

Despite the common practice of combining dexamethasone (Dex) with bortezomib (Bz) in
patients with multiple myeloma (MM), until now there has been few prospective trials …

Total parenteral nutrition (TPN) is now a standard component of supportive treatment in many
pediatric oncology units for patients undergoing intensive therapy. TPN incurs many risks …

The cases of 28 patients with neoplastic spinal cord compression were reviewed. The most
common presenting symptoms were: back pain (68%), bilateral leg weakness (61 %), urinary …

TO THE EDITOR: Law and Batey1 rely on a flawed study for their conclusion that needle/syringe
programs (NSPs) have saved lives and money. The study in question2 compared the …

Background MDX-1097 is a chimeric monoclonal antibody that binds specifically to
malignant plasma cells present in the bone marrow of patients with kappa restricted multiple …

The tumorigenicity of malignant melanoma cells may be suppressed experimentally by the
introduction into these cells of human chromosome 6 or mouse chromosome 4. These …

It has been shown that when malignant tumour cells are fused with normal fibroblasts the
suppression of malignancy in the hybrids is linked to their ability to produce a collagenous …